Takeaway

• The once-weekly injectable tirzepatide produced significant weight loss in adults with obesity.

Why this matters

• Obesity increases risks for morbidity and mortality.
• Tirzepatide, a dual long-acting glucagon-like peptide-1 receptor agonist and glucose-dependent insulinotropic polypeptide, was approved in the United States and is under European regulatory review for treating type 2...